Premium
Intramuscular immunisation with MUC 1 cDNA can protect C57 mice challenged with MUC1‐expressing syngeneic mouse tumour cells
Author(s) -
Graham Rosalind A.,
Burchell Joy M.,
Beverley Peter,
TaylorPapadimitriou Joyce
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19960301)65:5<664::aid-ijc17>3.0.co;2-7
Subject(s) - immunogen , muc1 , immune system , biology , complementary dna , immunotherapy , antigen , immunology , antibody , cytotoxic t cell , microbiology and biotechnology , monoclonal antibody , gene , in vitro , biochemistry
Much interest is currently being shown in immunotherapy as a treatment for cancer since several tumour‐associated antigens have been identified and the genes encoding them cloned. One such molecule is the tumour‐associated human MUC 1 gene product. In this report we describe tumour rejection studies in a C57BI murine model system with syngeneic MUC1‐expressing tumour cells designed to examine the efficacy of MUC 1 cDNA as an immunogen. Intra‐muscular immunisation with 100 μg MUC 1 cDNA 3 times at 3‐weekly intervals resulted in tumour protection in approximately 80% of mice. Tumour protection was dose‐dependent, with 50–100 μg being the most effective dose. Both humoral and cell‐mediated MUC1‐specific immune responses were detected. Anti‐MUC1 antibodies were detected after immunisation with DNA alone, indicating that the injected DNA was expressed. Humoral immune responses did not correlate with tumour rejection. Tumour challenge with syngeneic tumour cells expressing MUC1 appeared to be a pre‐requisite for the generation of MUC1‐specific cytotoxic T lymphocytes. © 1996 Wiley‐Liss, Inc.